Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Pain
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants with headache relief 2 hours 72% with almotriptan 6.25 mg 55% with placebo Absolute results reported graphically	P = 0.001 Result not adjusted for baseline severity Results should be interpreted with caution (see Further information on studies)	Effect size not calculated	almotriptan
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants with headache relief 2 hours 73% with almotriptan 12.5 mg 55% with placebo Absolute results reported graphically	P <0.001 Result not adjusted for baseline severity Results should be interpreted with caution (see Further information on studies)	Effect size not calculated	almotriptan
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants with headache relief 2 hours 67% with almotriptan 25 mg 55% with placebo Absolute results reported graphically	P = 0.028 Result not adjusted for baseline severity Results should be interpreted with caution (see Further information on studies)	Effect size not calculated	almotriptan
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants with sustained headache relief 2–24 hours 67% with almotriptan 6.25 mg 54% with placebo Absolute results reported graphically	P = 0.005 Result not adjusted for baseline severity Results should be interpreted with caution (see Further information on studies)	Effect size not calculated	almotriptan
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants with sustained headache relief 2–24 hours 67% with almotriptan 12.5 mg 54% with placebo Absolute results reported graphically	P = 0.006 Result not adjusted for baseline severity Results should be interpreted with caution (see Further information on studies)	Effect size not calculated	almotriptan
RCT 4-armed trial	866 participants aged 12–17 years with a >1-year history of migraine; final analysis consisted of 714 (82%) participants who completed the study protocol	Proportion of participants with sustained headache relief 2–24 hours 64% with almotriptan 25 mg 54% with placebo Absolute results reported graphically	P = 0.02 Result not adjusted for baseline severity Results should be interpreted with caution (see Further information on studies)	Effect size not calculated	almotriptan